Dana K. Furstenau - Publications

Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study.

Journal: American journal of hematology

Published: February 29, 2024

In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation.

Journal: Blood advances

Published: August 07, 2023

Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease.

Journal: Blood advances

Published: May 18, 2022

Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease.

Journal: Pharmacotherapy

Published: June 01, 2021

Allogenic hematopoietic stem cell transplantation in sickle cell disease.

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Published: January 24, 2021

The small GTPase Rap1 promotes cell movement rather than stabilizes adhesion in epithelial cells responding to insulin-like growth factor I.

Journal: The Biochemical journal

Published: July 17, 2014

Vav2 protein overexpression marks and may predict the aggressive subtype of ductal carcinoma in situ.

Journal: Biomarker research

Published: January 01, 2014